28/MAY/13
An independent study valuates Neuron Bio three times more than its stock market quotation
Venture Valuation, a prestigious Swiss company, qualifies not only the potential market of Neuron Bio projects but also its proven scientific and management.
The prestigious Swiss consultancy Venture Valuation specializes in evaluating biotechnology companies has finalized a report carried out in the first term of 2013, which calculated that the average value of Neuron Bio would reach 31.3 million Euros (6.77 Euros per share) including the 50 % participation in Neol Biosolutions together with Repsol. The Venture Valuation experts estimate that the current value of the company would be tripled depending on its quotation on the MAB for companies in expansion.
In this report, the consultancy has highlighted the strengths of Neuron Bio, not only its scientific team and its capacity to develop neuroprotective compounds, but also its management team both at management level and business and scientific development.
The Venture Valuation report positively analyzes the enormous commercial potential of the compounds under development and the capacity of the company to generate synergies with large companies with an obvious reference to the agreement with Repsol for the setting up of Neol.
Venture Valuation is one of the most rigorous companies for the valuation of biotech businesses in Europe due to the application of three combined methods of financial analysis and its knowledge of the sector as it manages the database Biotechgate.com, which provides detailed information on more than 29,000 biotechnological companies at a world-wide level.
|